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Abstract
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-saving technology that provides transient
respiratory and circulatory support for patients with profound cardiogenic shock or refractory cardiac arrest. Among
its potential complications, VA-ECMO may adversely affect lung function through various pathophysiological
mechanisms. The interaction of blood components with the biomaterials of the extracorporeal membrane elicits a
systemic inflammatory response which may increase pulmonary vascular permeability and promote the
sequestration of polymorphonuclear neutrophils within the lung parenchyma. Also, VA-ECMO increases the
afterload of the left ventricle (LV) through reverse flow within the thoracic aorta, resulting in increased LV filling
pressure and pulmonary congestion. Furthermore, VA-ECMO may result in long-standing pulmonary hypoxia, due
to partial shunting of the pulmonary circulation and to reduced pulsatile blood flow within the bronchial
circulation. Ultimately, these different abnormalities may result in a state of persisting lung inflammation and
fibrotic changes with concomitant functional impairment, which may compromise weaning from VA-ECMO and
could possibly result in long-term lung dysfunction. This review presents the mechanisms of lung damage and
dysfunction under VA-ECMO and discusses potential strategies to prevent and treat such alterations.
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Introduction
Veno-arterial extracorporeal membrane oxygenation
(VA-ECMO) is a life-saving technology providing re-
spiratory and circulatory support in patients with refrac-
tory cardiogenic shock or cardiac arrest [1] and which
may give time to plan future therapeutic decisions such
as the insertion of long-term cardiac assist devices or
heart transplantation (HTX) [2]. Notwithstanding its po-
tential benefits, VA-ECMO remains associated with sig-
nificant morbidity and mortality [1]. This is partly due
to the patients’ critical condition, but also to complica-
tions related to VA-ECMO, notably renal failure, sepsis,
bleeding, thromboembolism, limb ischemia, and multi-
organ failure [3, 4].
VA-ECMO-induced pulmonary complications are much
less recognized, except from the pulmonary congestion re-
lated to left ventricle pressure overload induced by retro-
grade VA-ECMO flow within the thoracic aorta [5].
Beside this particular aspect, several additional mecha-
nisms may contribute to lung damage and dysfunction in
the setting of VA-ECMO. The latter may be assimilated to
a simplified cardiopulmonary bypass (CPB) circuit, and
both techniques share common pitfalls with respect to
lung physiology. CPB may alter pulmonary function after
cardiac surgery by promoting an inflammatory response
via biomaterial-dependent and biomaterial-independent
factors, the collapse of lungs during the procedure, the
shunting of pulmonary circulation, and the phenomenon
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of lung reperfusion injury which takes place once CPB is
weaned [6]. During VA-ECMO, although such processes
are attenuated, they still occur at different stages of sup-
port and at various degrees, and they may persist for days
or weeks. In such conditions, the combination of a chronic
inflammatory response, pulmonary congestion, and lung
ischemia could foster a wealth of morphological and func-
tional alterations which could interfere with patient’s re-
covery and compromise the overall planned therapeutic
strategy. In this review, we discuss the pathophysiological
mechanisms and potential clinical implications of the pul-
monary complications associated with VA-ECMO.
VA-ECMO-related systemic inflammatory response
syndrome
The induction of a systemic inflammatory response syn-
drome (SIRS) by the contact of blood with biomaterial is
a typical consequence of extracorporeal circulation [7].
While extensively studied in the field of CPB, this is also
witnessed during VA-ECMO, as recently reviewed [8].
In addition, patients undergoing VA-ECMO are critically
ill and suffer from profound cardiogenic shock, which by
themselves contribute to the development of SIRS [9].
The lung is a major target of inflammatory injury in the
context of SIRS, owing to its extensive capillary bed and
the presence of abundant immune cells within the lung
parenchyma. Therefore, the occurrence of SIRS in the
context of ECMO provides a highly favorable environ-
ment for the development of acute lung injury [10, 11].
The main mechanisms triggering the inflammatory re-
sponse to biomaterials are presented below.
Humoral cascades
Blood contact with VA-ECMO circuitry activates the
contact system (CS) and the complement system (Fig. 1).
CS generates kallikrein [12], which activates monocytes
Fig. 1 Main VA-ECMO-induced mechanisms of lung damage and dysfunction. Left side: SIRS is initiated by the blood contact with the circuitry
surface. It activates humoral cascades, platelets, and leukocytes, leading eventually to EC injury and activated PMN sequestration into the lung
parenchyma. Right side: EC injury favors fluid infiltration into both alveolar space and lung parenchyma, leading to pulmonary edema, which is
aggravated by the increase of pulmonary vein pressure. Alveolar edema and decreased pulmonary artery perfusion lead to lung parenchymal
ischemia which in turn maintains chronic inflammation and promotes neoangiogenesis and fibrosis generation
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and polymorphonuclear cells (PMNs), and triggers the
intrinsic coagulation cascade, resulting in the rapid gener-
ation of thrombin and fibrin within the systemic circula-
tion [13]. Thrombin activates platelets and endothelial
cells (ECs) and induces the secretion of pro-inflammatory
mediators and growth factors, such as interleukin-6 (IL-6),
interleukin-8 (IL-8), or platelet-derived growth factor
(PDGF) [13]. The extrinsic coagulation pathway is acti-
vated to a lesser extent, mainly through the release of tis-
sue factor (TF) by activated monocytes and ECs. CS also
generates bradykinine [12], which activates ECs and leu-
kocytes, and elicits hemodynamic alterations including
systemic vasodilation and pulmonary vasoconstriction
[14]. Complement activation occurs via the alternative
pathway, generating the anaphylatoxins C3a and C5a,
which activate ECs. C5a is also a potent mediator of
leukocyte chemotaxis. A peak of complement activation
occurs within 1–2 h of ECMO onset, followed by a pro-
gressive decreases over the next 2 to 3 days [15].
The humoral response triggered by blood-biomaterial
interaction comprises the release of multiple cytokines [16].
Whereas a balance between pro- and anti-inflammatory cy-
tokines is reached several hours after VA-ECMO initiation
[17], an initial imbalance in favor of pro-inflammatory
TNF-α, IL-1β, and IL-6 leads to the activation of ECs and
promotes the release of multiple inflammatory proteins by
the liver such as fibrinogen, complement, and C-reactive
protein. TNF-α plays a major role in the amplification of
the early inflammatory response, by upregulating pro-
inflammatory cytokines and prostaglandin synthesis, acti-
vating PMNs and ECs, and stimulating reactive oxygen spe-
cies (ROS) production [18, 19].
Cell activation
Platelets are activated by contact with the tubing surface
and by thrombin and complement. Activated platelets fos-
ter the generation of pro-inflammatory cytokines, thromb-
oxane A2 (TXA2), platelet-activating factor (PAF), P-
selectin, and serotonin. TXA2 induces ECs activation and
local vasoconstriction, while serotonin and P-selectin pro-
mote PMN-endothelial interactions [20]. Platelet activa-
tion is maximal at the initiation of VA-ECMO and
progressively decreases over hours to days but remains
persistent [21]. EC activation leads to their detachment
from the basal membrane and disassembly of tight junc-
tions, increasing vascular permeability with the develop-
ment of sub-endothelial edema [22]. Moreover, activated
ECs display an upregulated expression of adhesion mole-
cules favoring PMN adhesion and transendothelial migra-
tion [23], and they also release cytokines, tissue factor, and
ROS. Circulating PMNs, monocytes, and macrophages are
spontaneously activated by tubing surfaces [24]. Further-
more, PMNs are activated by complement, histamine,
serotonin, and PAF, which facilitate their adhesion to ECs,
diapedesis, tissue infiltration [25], and the release of cyto-
toxic mediators, including proteases, cytokines, and ROS.
Modulation of SIRS during VA-ECMO
At variance with CPB, VA-ECMO is generally main-
tained over several days. The initial significant SIRS
gradually decreases [15, 17], mostly through the progres-
sive build-up of counter-regulatory mechanisms leading
to compensatory anti-inflammatory response and of pos-
sible biomaterial inactivation [26]. Still, a delayed persist-
ing inflammatory response can be observed several days
after VA-ECMO implementation, whose underlying
mechanisms may involve the presence of low concentra-
tion of endotoxin within the circulation, which may sus-
tain complement activation, cytokine release, and ROS
generation, to elicit a sepsis-like inflammation [27, 28].
The low-level inflammatory response induced by pulmon-
ary low flow is another potential mechanism (see below).
Strategies to reduce SIRS-induced lung damages during
VA-ECMO
Some potential therapies have been proposed to downreg-
ulate inflammation and possibly improve lung outcome in
this setting. The replacement of a silicon oxygenator by a
poly-methyl pentene oxygenator has been associated with
reduced radiological signs of pulmonary inflammation on
chest X-ray [29], while the administration of steroids in
patients undergoing VA-ECMO has been associated with
shortened mechanical ventilation time, although without
any survival benefit [30].
VA-ECMO-related pulmonary congestion
Pathophysiology
Peripheral (femoro-femoral) VA-ECMO provides a
non-physiological blood flow promoting significant
hemodynamic perturbations (Fig. 1). The retrograde
reinjection of blood into the thoracic aorta increases
LV afterload and impedes aortic valve opening, while
increasing myocardial oxygen demand [31]. In the set-
ting of cardiogenic shock, these disturbances may
worsen LV performance and dramatically reduce LV
stroke volume [31, 32]. In addition, if LV residual
function is insufficient to permit aortic valve opening,
progressive LV distension will occur, due to persisting
venous return through pulmonary and bronchial veins
into the left atrium and through Thebesian veins into
the LV, with concomitant increase of LV end-diastolic
pressure. At worst, stagnation of blood within dilated
left cardiac chambers may favor the formation of
clots and induce pulmonary vein thrombosis [33].
Pulmonary congestion develops consecutively to the
passive upstream transmission of elevated LV pressure
[34]. Lung extravascular water accumulation is potentiated
by the increased vascular permeability in the context of
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VA-ECMO-induced SIRS. The magnitude of afterload
increase, LV distension, and pulmonary congestion is
dependent on several parameters, including VA-ECMO
flow, systemic vascular resistance, and LV residual
function [31, 35].
Pulmonary congestion may jeopardize lung parenchy-
mal cell oxygenation through two mechanisms. Firstly,
interstitial edema increases the thickness of the alveolar-
capillary barrier, hence the diffusion distance for oxygen
between alveoli and parenchymal cells, whose oxygen-
ation primarily depends on oxygen diffusing from alveo-
lar spaces [36]. Secondly, alveolar edema results in a
marked reduction of local alveolar PO2 (PAO2). Alveolar
epithelial cells, normally exposed to PAO2 above 100
mmHg, are sensitive to hypoxia from PAO2 below 50
mmHg, which may occur in alveoli flooded by pulmon-
ary edema [37]. Alveolar hypoxia can destabilize inter-
cellular junctions, impair barrier permeability, impede
alveolar fluid clearance and surfactant production by
pneumocytes, induce local vasoconstriction and neoangio-
genesis, and finally trigger local and systemic inflamma-
tion [37–39]. Therefore, pulmonary congestion during
VA-ECMO creates a vicious circle in which VA-ECMO-
induced SIRS and LV pressure overload promote pulmon-
ary edema, leading to alveolar hypoxia which maintains
SIRS [37]. Alveolar hemorrhages are another frequent
consequence of the combination of pulmonary congestion
and the requirement of anticoagulation during ECLS.
Even if massive hemoptysis is rare [40], local alveolar
hemorrhages are frequent and sustain local inflammatory
changes [41, 42].
Evaluation of pulmonary congestion and cardiac overload
during VA-ECMO
Chest X-ray is the simplest exam to assess pulmonary
congestion, although its interpretation is complicated by
frequently associated abnormalities, such as pneumonia,
atelectasis, or alveolar hemorrhages. Chest ultrasound is
an effective and reliable alternative method to assess inter-
stitial edema, pleural effusion, and parenchymal consolida-
tion [43]. Echocardiographic examination is mandatory, as
it may show left heart dilation and indirect signs of cardiac
congestion, such as spontaneous contrast echoes or the
presence of “sludge” in heart chambers, as well as the ab-
sence of aortic valve opening [44]. Hemodynamic moni-
toring using pulmonary artery catheter (PAC) has been
associated with improved survival in cardiogenic shock
[45], notably in the context of mechanical cardiac support.
PAC is particularly helpful to identify patients with cardiac
distension, by demonstrating elevated left-sided filling
pressure [46]. It has been shown that combining a value of
pulmonary artery diastolic pressure > 25mmHg (as a sur-
rogate of pulmonary capillary wedge pressure) with evi-
dence of pulmonary edema on chest X-ray could identify
patients with subclinical LV distension [47]. Although
these data need further validation, PAC is now advocated
by most experts to help manage patients under VA-
ECMO [48].
Strategies to reduce pulmonary congestion during VA-
ECMO
Severe pulmonary congestion during VA-ECMO is asso-
ciated with a dismal prognosis, and its treatment is
mandatory [5, 49]. Inotropic agents increase cardiac con-
tractility, promote aortic valve opening, and reduce LV
dilation and filling pressure. Reducing VA-ECMO flow
to decrease LV afterload, as long as residual LV ejection
is present and peripheral perfusion maintained, should
also be considered. The insertion of an intra-aortic
balloon pump (IAPB) is a further option to decrease
LV afterload. As demonstrated by Bréchot et al., IABP
in combination with VA-ECMO versus VA-ECMO
alone is independently associated with less frequent
hydrostatic pulmonary edema and a shorter duration
of mechanical ventilation [50]. A recent meta-analysis
found concomitant IABP to reduce in-hospital death
and length of stay [51].
If previous steps fail to reduce pulmonary edema, the
left heart chambers must be directly unloaded (“vented”),
either by percutaneous atrial transseptal approach or by
using a venting cannula inserted into the left atrium or
the LV apex by surgical or trans-aortic approach [52]. In
addition, the catheter-mounted microaxial pump Impella®
(Abiomed, Danvers, MA) may represent a further efficient
device to permit LV unloading [52]. Eliet et al. have re-
cently observed that Impella® not only decreases LV dia-
stolic diameter but also increases pulmonary flow [53].
These different modalities of cardiac unloading during
VA-ECMO have been the matter of several extensive
recent reviews [52, 54].
VA-ECMO-related lung ischemia
Lung blood supply
The lung is characterized by a dual circulation, compris-
ing the pulmonary circulation, which supplies the alveoli
for gas exchange, and the bronchial circulation, which
conveys oxygen and nutrients to the airways, but not al-
veoli, whose oxygen supply is almost exclusively pro-
vided by direct diffusion from the alveolar spaces [39].
Bronchopulmonary anastomoses allow collateralization
between these two circulations. In case of chronic de-
crease of pulmonary blood flow (e.g., in chronic
thromboembolic disease or pulmonary stenosis), the
bronchial flow may increase from 1 to 30% of the car-
diac output, permitting to compensate this decrease and
participate to gas exchange, providing a kind of “rescue
flow” to the ischemic areas [55, 56].
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Disturbances induced by VA-ECMO
As depicted in Fig. 1, venous blood during VA-ECMO is
derived from the vena cava and the right atrium through
the venous canula, resulting in a reduction of right ven-
tricle (RV) filling, pulmonary blood flow, and pulmonary
arterial pulsatility [31]. In a porcine model, Vardi et al.
demonstrated that the pulmonary capillary blood flow
decreases dramatically as the VA-ECMO flow increases
[57]. Moreover, in case of pulmonary congestion (see
above), the upstream transmission of increased left atrial
pressure reduces the transpulmonary perfusion gradient.
Ventilation with high positive end-expiratory pressure
(PEEP) might also impede pulmonary blood flow by
compression of alveolar vessels [58]. Several additional
mechanisms, including alveolar hypoxia, reduction of
local NO production, and the actions of inflammatory
mediators can promote vasoconstriction and the subse-
quent increase of pulmonary vascular resistance, with a
reduction of pulmonary blood flow [59]. It is also note-
worthy that blood flow through the bronchial arteries
(BAs) is also reduced during VA-ECMO, due to attenu-
ated pulsatility of the systemic circulation (which sup-
plies the BAs). This can further limit blood supply to
ischemic areas within the congested lung [60]. Eventu-
ally, these various hemodynamic changes may lead to
hypoperfusion of the entire pulmonary vasculature,
which, superimposed to alveolar hypoxia, can promote a
state of global, persistent lung ischemia.
Strategies to reduce lung ischemia
The best way to overcome such alterations is, of course,
the withdrawal of VA-ECMO. If this is not possible, VA-
ECMO flow may be reduced to maintain partial pul-
monary perfusion. In early experimental studies in pigs,
prolonged (18 h) ECMO at full support (with no residual
pulmonary blood flow) promoted massive pulmonary
parenchymal damage [61], which was not observed at a
residual pulmonary blood flow reaching 25% of the sys-
temic cardiac output [62]. An additional strategy relies
in the upgrading of VA-ECMO to a hybrid system of
veno-veno-arterial support, with an additional cannula
inserted into the jugular vein, which provides oxygen-
ated blood within the pulmonary arteries. This approach
is sometimes used to treat the Harlequin syndrome (see
below), but has not yet been evaluated to prevent lung
injury during VA-ECMO.
Structural lung parenchymal changes
Although no dedicated study has specifically focused on
pulmonary histological consequences of VA-ECMO,
data from animal models and small human necropsy
series have reported several pathological alterations.
Koul et al. maintained 6 pigs under total CPB for 18 h
before weaning. All the animals died within the next 4 h,
and on histological examination, more than 80% of the
pulmonary parenchyma displayed edema, hyaline mem-
branes, alveolar hemorrhages, thrombi, and focal nec-
rotic changes [61]. In another experimental study
exploring the effects of long-term VA-ECMO without
anticoagulation, Mizuno et al. succeeded to maintain a
goat up to 5 months under VA-ECMO with a pulmonary
blood flow reduced to 40%. At autopsy, diffuse intersti-
tial fibrosis and swelling of endothelial cells with thick-
ening of their basal membrane were noted [63].
In humans, Ratliff et al. reported postmortem findings
in 4 patients undergoing VA-ECMO for 7 to 12 days. In
two patients, diffuse lung fibrosis was noted, together
with liquefaction necrosis of the lower lobes. The au-
thors hypothesized that the combination of an increase
in metabolically active cell mass together with partial
pulmonary shunting concurred to establish ischemic
areas with subsequent necrosis [64]. In an autopsy series
of 23 infants supported by VA-ECMO, Chou et al. re-
ported hyaline membrane formation, interstitial and
intra-alveolar hemorrhages, and reactive hyperplasia of
epithelial and smooth muscle cells, developing already
after 2 to 3 days of VA-ECMO support, whereas intersti-
tial fibrosis was noted beyond 7 days [41].
To sum up, VA-ECMO appears mostly associated with
signs of protein-rich edema, alveolar hemorrhages, tissue
necrosis, and fibrosis, which are reminiscent of the dam-
age noted in the acute respiratory distress syndrome.
These changes are likely the result of the combination of
inflammatory injury, pulmonary congestion, and hyp-
oxia, with the progressive development of epithelial-
endothelial injury, increased vascular permeability, and
interstitial collagen deposition [65]. Furthermore, some
degree of angiogenesis and vascular remodeling may also
play some role, as alveolar hypoxia and chronic ischemia
(typical of long-lasting VA-ECMO) can activate several
pro-angiogenic cascades in alveolar cells, relying on the
hypoxia-inducible factor family or the resistin-like
molecule-α [37]. Such alterations could result in long-
term changes in pulmonary vascular physiology, with
possible detrimental consequences on the right ventricle.
Potential clinical consequences
Pulmonary dysfunction during VA-ECMO
The impaired pulmonary function induced by VA-ECMO
may require long-lasting mechanical ventilation (MV)
which may further alter the lung through ventilator-
induced lung injury (VILI). Although there is presently no
consensus regarding optimal ventilator settings for MV
during VA-ECMO, the principles of lung-protective venti-
lation should be applied [66].
Furthermore, prolonged MV increases the risk of
ventilator-associated pneumonia (VAP), which occurs in
up to 74% of patients under ECMO, as recently reviewed
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[67], with risk factors including an age > 65 years, a
higher SOFA score on admission, and a history of COPD
or hypertension [68]. Causative microorganisms com-
prise primarily Gram-negative bacilli, with Pseudomonas
aeruginosa isolated in 18–25% of cases [67]. Diagnosis of
VAP may be particularly troublesome, as the usual cri-
teria of VAP are difficult to interpret in the setting of
ECMO, and a high clinical index of suspicion coupled to
early microbiological sampling are major clues to diag-
nosis [67]. Treatment of VAP on ECMO is challenging,
notably because of the alterations of antibiotic pharma-
cokinetics occurring in this setting, and frequent thera-
peutic drug monitoring is therefore recommended [69].
Preventive measures to reduce the risk of VAP include
primarily the reduction of MV duration. In this regard, a
strategy of early extubation and awake ECMO support is
emerging as a promising strategy [70]. In properly se-
lected patients, such strategy not only significantly re-
duces the incidence of VAP [70], but also permits active
mobilization, reduces the overall rate of complications,
and increases survival [71].
The prototypical consequence of VA-ECMO-
dependent impairment of lung function is the develop-
ment of the “Harlequin syndrome,” reflecting the oppos-
ing flows from the heart (antegrade, poorly oxygenated
blood flow) and from the peripheral ECMO (retrograde,
highly oxygenated blood flow), resulting in differential
hypoxia (upper body hypoxemia, lower body normo/
hyperoxemia). The level of mixing of the two flows
within the aorta is termed the “watershed,” which can be
identified in contrast-enhanced CT scan of the chest
(Fig. 2). The Harlequin syndrome may be treated by in-
creasing VA-ECMO flow or adding a venous injection
cannula either as a hybrid ECMO (veno-veno-arterial
ECMO, Fig. 3) or as pure veno-venous ECMO if the
function of the heart allows withdrawal of the arterial
cannula. Another option consists of switching the
arterial cannulation site from femoral to axillary or cen-
tral (aorta) location, in order to avoid the retrograde
flow from the peripheral femoral cannula [72].
Finally, bronchoscopy with bronchial hygiene may be
considered routinely in order to maximize chances of
successful weaning from VA-ECMO when cardiac func-
tion recovers [73].
Pulmonary dysfunction after weaning from VA-ECMO
VA-ECMO-induced lung alterations may only appear
after weaning and the restoration of physiological pul-
monary artery blood flow. In a series of 55 patients who
underwent long-term mechanical assist device im-
plantation under VA-ECMO (L-VAD, bi-VAD, or
total artificial heart), Boulate et al. noticed that 27%
of patients develop acute lung injury (ALI) few hours
after restoration of pulmonary blood flow, with a sig-
nificant impact on mortality. The authors hypothe-
sized that chronic lung ischemia during VA-ECMO
support could promote alveolar frailty and that the
sudden restoration of an antegrade pulsatile pulmon-
ary blood flow creates a massive pulmonary bed over-
load responsible of ALI [74]. Accordingly, one of the
identified risk factors of ALI in this study was the oc-
currence of a pulmonary edema during the week pre-
ceding the implantation of the mechanical device,
featuring a preexisting lung frailty.
This form of ALI is reminiscent of reperfusion pul-
monary edema, a well-known and described condition
that occurs after reperfusion of a chronic low pulmonary
blood flow situation, as in correction of tetralogy of Fal-
lot [75] or pulmonary endarteriectomy for chronic em-
bolism [76]. Such reperfusion pulmonary edema relies
both on ischemia-induced chronic inflammation and re-
perfusion injury that involves similar mechanisms than
those described above [77].
Fig. 2 The watershed. a Axial. b Sagittal. Contrast in the aorta indicates blood flow from the VA-ECMO arterial cannula, whereas absence of
contrast within the ascending aorta indicates blood flow from the native heart. The level of blood mixing in the thoracic aorta represents the VA-
ECMO watershed (arrows)
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In order to help the decision-making process in patients
under VA-ECMO, Chen et al. developed a risk factor-
calling score (RFSS) to select patients eligible for L-VAD
or HTX. The RFSS has 5 items and 16 points, 7 of which
are allocated to pulmonary dysfunction. A RFSS > 7 pre-
dicted a poor outcome, which emphasizes the relative bur-
den of pulmonary dysfunction in the outcome of patients
under VA-ECMO in a bridge strategy [78].
Long-term outcome
It is currently unknown whether lung damage and dys-
function induced by VA-ECMO have an impact on
long-term outcome, the more so that many unrelated
factors may interfere with such outcome, such as pro-
longed ICU stay, previous health condition, or reduced
LV ejection fraction. A few studies focused on long-term
health-related quality of life (HRQL) in VA-ECMO sur-
vivors after cardiogenic shock. Combes et al. questioned
28 VA-ECMO survivors about their HRQL via the
short-form 36 questionnaire (SF-36). Mean VA-ECMO
duration and follow-up were respectively 7 days (5 to 10)
and 11months (3 to 39). In comparison to sex- and age-
matched controls, VA-ECMO survivors disclosed signifi-
cantly lower role-physical score and a trend to a lower
physical function, even though most patients recovered a
good cardiac function with mean LVEF 51% or under-
went HTX [79]. These results were confirmed by other
studies showing lower SF-36 values of physical function-
ing and role-physical scores in VA-ECMO survivors
compared to standard population [80, 81]. These data
however do not give any information with respect to the
potential long-term burden of pulmonary alterations as-
sociated with VA-ECMO, and future studies should be
designed to address this issue, for example by perform-
ing delayed lung functional tests in long-term survivors
of VA-ECMO.
Conclusion
VA-ECMO elicits several pathophysiological distur-
bances which may significantly impact on lung integrity
and function. First, the rapid development of a systemic
inflammatory response with pulmonary involvement is
an unavoidable consequence of the artificial VA-ECMO
circuitry. Second, due to retrograde blood flow within
the thoracic aorta, peripheral VA-ECMO has the pro-
pensity to increase LV afterload, which may favor the
congestion of alveoli already affected by the ongoing
inflammation.
Third, persistent lung ischemia due to the partial
shunting of the pulmonary circulation and reduced pul-
satility of the bronchial circulation may elicit further
cytotoxicity within the whole lung parenchyma. Limited
evidence from human observational studies and animal
models indicates that VA-ECMO support for more than
a few days may lead to severe structural changes of the
lung parenchyma and interstitial fibrosis, which could
result in long-term functional limitation. Clinicians in
charge of VA-ECMO patients should be aware of its ef-
fects on lung physiology and should take all measures to
limit such consequences, including the maintenance of
Fig. 3 Veno-veno-arterial ECMO. Oxygenated blood is propelled through both the femoral arterial cannula and the additional jugular cannula
providing oxygenated blood directly into the right-heart chambers and consequently into the left atrium. This setting permits to wean
progressively the arterial cannula in order to switch to veno-venous ECMO
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VA-ECMO support as short as possible, the early
diagnosis and treatment of cardiac overload and pul-
monary congestion, and the application of lung-
protective ventilation. Future studies specifically ad-
dressing the issue of the pulmonary consequences of
VA-ECMO are warranted.
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